Research
Clinical trials
Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.
Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.
Recruiting and upcoming studies
The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.
Showing 13–24 of 208 trials
RecruitingAL (light chain)
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis (opens on ClinicalTrials.gov)
Before effective treatment, the prognosis of patients with AL amyloidosis is very poor, with a median survival of approximately 12 months. In recent decades,…
- Study
- Interventional (treatment)
- Sponsor
- Peking University First Hospital
Recruiting in: China
NCT07215494Updated 16 September 2026
RecruitingNot specified
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH (opens on ClinicalTrials.gov)
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are…
- Study
- Observational (registry, imaging)
- Sponsor
- Peking University First Hospital
Recruiting in: China
NCT05283993Updated 16 September 2026
RecruitingATTR (transthyretin)
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (opens on ClinicalTrials.gov)
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Alnylam Pharmaceuticals
Recruiting in: ArgentinaAustraliaAustriaBelgium+32
NCT07052903Updated 16 September 2026
RecruitingATTR (transthyretin)
Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy (opens on ClinicalTrials.gov)
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart disease caused by the buildup of an abnormal protein, called transthyretin (TTR), in the heart. This…
- Study
- Observational (registry, imaging)
- Sponsor
- Bayer
Recruiting in: France
NCT07791160Updated 15 September 2026
RecruitingATTR (transthyretin)
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (opens on ClinicalTrials.gov)
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment,…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Alnylam Pharmaceuticals
Recruiting in: ArgentinaAustraliaBrazilCanada+17
NCT07223203Updated 15 September 2026
RecruitingATTR (transthyretin)
Exploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis (opens on ClinicalTrials.gov)
Transthyretin cardiac amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy caused by amyloid fibril deposition, leading to heart failure and arrhythmias. Despite advances in diagnosis, the…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Nantes University Hospital
Recruiting in: France
NCT07549841Updated 14 September 2026
Not yet recruitingNot specified
Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis (opens on ClinicalTrials.gov)
The goal of this clinical trial is to learn if a structured cardiac rehabilitation program can help people with cardiac amyloidosis improve their ability…
- Study
- Interventional (treatment)
- Sponsor
- University Hospital, Montpellier
Recruiting in: France
NCT07494942Updated 14 September 2026
RecruitingATTR (transthyretin)
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations (opens on ClinicalTrials.gov)
The aim of this observational cohort study is to characterise use of eplontersen in patients with prior liver transplant or with pre-existing severe hepatic…
- Study
- Observational (registry, imaging)
- Sponsor
- AstraZeneca
Recruiting in: CanadaChinaGermanySpain+2
NCT07654855Updated 14 September 2026
Enrolling by invitationAL (light chain)
Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis (opens on ClinicalTrials.gov)
1. Goal of the Study: The goal of this prospective observational study is to develop and validate a novel, non-invasive method for predicting the…
- Study
- Observational (registry, imaging)
- Sponsor
- Beijing Anzhen Hospital
Recruiting in: China
NCT07103863Updated 10 September 2026
RecruitingATTR (transthyretin)
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting (opens on ClinicalTrials.gov)
The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran…
- Study
- Observational (registry, imaging)
- Sponsor
- Alnylam Pharmaceuticals
Recruiting in: GermanyJapanUnited States
NCT07358078Updated 9 September 2026
RecruitingATTR (transthyretin)
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis (opens on ClinicalTrials.gov)
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns…
- Study
- Observational (registry, imaging)
- Sponsor
- AstraZeneca
Recruiting in: CanadaChinaDenmarkGermany+7
NCT06355934Updated 9 September 2026
RecruitingAL (light chain)
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis (opens on ClinicalTrials.gov)
[18F]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene ([18F]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin…
- Study
- Observational (registry, imaging)
- Sponsor
- Tianjin Medical University
Recruiting in: China
NCT07232459Updated 8 September 2026
This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 25 September 2026. clinicaltrials.gov
Not sure where to start?
Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.